Valuation: Autolus Therapeutics plc

Market Cap 426M 379M 351M 319M 602M 40.42B 612M 4.22B 1.65B 21.09B 1.6B 1.56B 67.24B P/E 2026 *
-1.96x
P/E 2027 * -2.3x
Enterprise Value 270M 240M 222M 202M 382M 25.61B 388M 2.67B 1.05B 13.36B 1.01B 991M 42.6B EV / Sales 2026 *
1.8x
EV / Sales 2027 * 1.81x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -
1 day-2.19%
1 week-11.49%
Current month-20.62%
1 month-20.62%
3 months+10.00%
6 months-2.53%
Current year-22.61%
1 week 1.54
Extreme 1.54
1.74
1 month 1.54
Extreme 1.54
2.08
Current year 1.18
Extreme 1.175
2.58
1 year 1.18
Extreme 1.175
2.58
3 years 1.1
Extreme 1.105
7.45
5 years 1.1
Extreme 1.105
7.9
10 years 1.1
Extreme 1.105
53.24
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 53 01/09/2014
Chief Executive Officer 61 01/03/2016
Director of Finance/CFO 56 07/08/2023
Director TitleAgeSince
Chairman 61 01/10/2014
Director/Board Member 78 01/08/2014
Director/Board Member 71 01/03/2018
Date Insider Type Main position Quantity % Market Cap. Importance
2/9/26 Sell

Executive/Senior Manager

-6,713 0.0025%
29/6/26 Free

Director

79,167 0.0477%
18/3/26 Other

Chief Executive Officer

6,917,877 4.1641%
Change 5-day change 1-year change 3-year change Capi.($)
-2.19%-11.49%-9.41%-38.40% 426M
-0.21%+5.52%+54.26%+111.22% 1,120B
-0.70%-3.62%+31.21%+66.87% 616B
-0.01%+1.67%+23.16%+96.41% 504B
+0.12%+5.50%+35.11%+59.28% 367B
+0.26%+0.64%+69.57%+45.75% 360B
-0.51%+3.33%+19.03%+46.27% 288B
-0.25%+3.06%-1.35%+18.17% 258B
+0.13%+3.41%+42.35%+53.88% 234B
+0.43%+4.06%+27.15%+99.56% 194B
Average -0.37%+1.82%+29.11%+55.90% 394.13B
Weighted average by Cap. -0.23%+3.52%+38.04%+76.76%

Financials

2026 *2027 *
Net sales 150M 133M 123M 112M 212M 14.21B 215M 1.48B 582M 7.42B 562M 550M 23.65B 192M 171M 159M 144M 272M 18.26B 277M 1.91B 747M 9.53B 722M 707M 30.38B
Net income -221M -196M -182M -166M -312M -20.96B -317M -2.19B -857M -10.94B -829M -811M -34.86B -189M -168M -155M -141M -267M -17.9B -271M -1.87B -732M -9.34B -708M -693M -29.78B
Net Debt -156M -139M -129M -117M -221M -14.81B -224M -1.55B -606M -7.73B -586M -573M -24.63B -77.38M -68.78M -63.75M -58M -109M -7.34B -111M -766M -300M -3.83B -290M -284M -12.22B
Projected Income Statement - Annual - Autolus Therapeutics plc
Logo Autolus Therapeutics plc
Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.
Employees
753
Date Price Change Volume
19/10/26 US$1.540 -3.75% 239,500
16/10/26 US$1.600 -6.98% 2,350,674
15/10/26 US$1.720 +1.78% 1,486,313
14/10/26 US$1.690 +4.32% 2,590,102
13/10/26 US$1.620 -6.90% 2,420,302
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Autolus Therapeutics plc
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1.600USD
Average target price
8.725USD
Spread / Average Target
+445.31%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Autolus Therapeutics plc
  1. Stock Market
  2. Stocks
  3. AUTL Stock